166 related articles for article (PubMed ID: 1915809)
1. Relationship between the proportion of paroxysmal nocturnal hemoglobinuria (PNH) III-erythrocytes and the frequency of exacerbated hemoglobinuria in PNH.
Shichishima T; Terasawa T; Uchida T; Maruyama Y
Eur J Haematol; 1991 Sep; 47(3):235-6. PubMed ID: 1915809
[No Abstract] [Full Text] [Related]
2. Paroxysmal nocturnal hemoglobinuria: an historical overview.
Parker CJ
Hematology Am Soc Hematol Educ Program; 2008; ():93-103. PubMed ID: 19074065
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of various therapies on complement-sensitive erythrocytes in paroxysmal nocturnal hemoglobinuria.
Shichishima T; Saitoh Y; Noji H; Terasawa T; Maruyama Y
Int J Hematol; 1996 Jun; 63(4):291-302. PubMed ID: 8762812
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
[TBL] [Abstract][Full Text] [Related]
5. The membrane abnormalities in paroxysmal nocturnal hemoglobinuria (PNH).
Rosse WF; Adams JP
Prog Clin Biol Res; 1979; 30():457-61. PubMed ID: 531036
[TBL] [Abstract][Full Text] [Related]
6. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease.
Halperin JA; Nicholson-Weller A
Complement Inflamm; 1989; 6(1):65-72. PubMed ID: 2650991
[TBL] [Abstract][Full Text] [Related]
7. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
8. Changes in electrophoretic mobility pattern of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria.
Hayashi H; Fujii M; Yoshikumi C; Kawai Y; Watanabe N; Watanabe K; Fusama M; Shishido H
J Clin Lab Immunol; 1987 Jun; 23(2):77-81. PubMed ID: 3625755
[TBL] [Abstract][Full Text] [Related]
9. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
[TBL] [Abstract][Full Text] [Related]
10. Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria.
Chow FL; Hall SE; Rosse WF; Telen MJ
Blood; 1986 Apr; 67(4):893-7. PubMed ID: 3955235
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
Parker CJ; Stone OL; Bernshaw NJ
J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation and quantification of complement-sensitive red cells in PNH and aplastic anemia-PNH syndrome].
Shichishima T; Terasawa T; Uchida T; Kariyone S
Rinsho Ketsueki; 1989 Mar; 30(3):297-302. PubMed ID: 2769953
[TBL] [Abstract][Full Text] [Related]
13. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of a structural abnormity in the stroma of erythrocytes from paroxysmal nocturnal hemoglobinuria (PNH) after hemolysis in distilled water.
BRAUNSTEINER H; GISINGER E; PAKESCH F
Blood; 1956 Aug; 11(8):753-6. PubMed ID: 13342075
[No Abstract] [Full Text] [Related]
15. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
16. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria.
Nakakuma H; Kawaguchi T; Horikawa K; Hidaka M; Yonemura Y; Kawakita M; Kagimoto T; Iwamori M; Nagai Y; Takatsuki K
J Clin Invest; 1990 May; 85(5):1456-61. PubMed ID: 2185273
[TBL] [Abstract][Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
19. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes.
Rosenfeld SI; Jenkins DE; Leddy JP
J Exp Med; 1986 Oct; 164(4):981-97. PubMed ID: 3760783
[TBL] [Abstract][Full Text] [Related]
20. Study of in vitro lysis of paroxysmal nocturnal haemoglobinuria (PNH) and PNH-like red cells.
Ferrone S; Marubini E; Mercuriali F; Sirchia G
Br J Haematol; 1972 Jul; 23(1):5-12. PubMed ID: 5045962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
